Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Glycemic Control Achieved With 2 Different Needles
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT00572052
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 208
- Registration Number
- NCT00569998
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sidcup, United Kingdom
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 241
- Registration Number
- NCT00569400
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Marikina City, Philippines
Evaluating the Use of Two Different Needles in Subjects With Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 119
- Registration Number
- NCT00569426
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00568984
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 131
- Registration Number
- NCT00568074
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00567775
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Glostrup, Denmark
Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 176
- Registration Number
- NCT00567385
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Altunizade-Istanbul, Turkey
Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 126
- Registration Number
- NCT00564668
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women
Phase 3
Terminated
- Conditions
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT00560924
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
© Copyright 2024. All Rights Reserved by MedPath